Introduction The frequency of breast cancer in elderly women increases over the years due to the increase in life expectancy in our country, as a result this cancer is becoming a major public health problem which will require special care. The impact of treatments in this patient population is still debated because the results of studies in terms of survival are divergent. The main objective of this work is to study the survival of patients aged over 70 years according to age, staging, molecular subgroups and quality of care. Patients and methods This is a prospective study, based on a survival analysis, carried out on women aged 70 and over with breast cancer living in the wilaya of Setif over a period of 5 years (from January 1 2013 to December 31, 2019), at the level of the medical oncology service of the center for the fight against cancer of the wilaya of Sétif. Results Our study was carried out on 109 patients, the rate of adjuvant chemotherapy reached 57.4% and 26.2% received neoadjuvant chemotherapy and 16.4% palliative chemotherapy. Primary hormone therapy represents 21.3% and 71.6% adjuvant and 54.54% metastatic, the level of adjuvant trastuzumab was 64%. The overall survival rate was 76.6% at 5 years. In our series, 5-year overall survival data did not show a significant difference between the 3 age categories (70-74 years, 75-79 years and over 80 years). Overall survival declined with advancing stage. According to the molecular class it was much better in the luminal subgroups compared to the other subgroups. Adherence to recommendations has been associated with better survival. Conclusion In our study we have therefore demonstrated that treatment in accordance with the recommendations is associated with better survival.